Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

First International Summit on Interventional Pharmacoeconomics

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

Mark J. Ratain, MD, of the University of Chicago, talks about why ibrutinib—which can lead to cardiotoxicities—should be studied at a lower dose for patients with chronic lymphocytic leukemia. Data suggest a reduced dose may prevent dose interruption due to adverse events and may have a better therapeutic index.

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Varsha Gandhi, PhD, on Ibrutinib

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Dec

Today In Oncology

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Related Videos

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Varsha Gandhi, PhD, on Ibrutinib

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Adding Tucatinib to First-Line Maintenance Therapy Delays Disease Progression in HER2-Positive Metastatic Breast Cancer

Mobile Health Intervention Offers Tailored Support for Adolescent and Young Adult Breast Cancer Survivors

Can Multimodal AI Models Predict Distant Recurrence Risk in Patients With Early Breast Cancer

Doublet Therapy Yields Higher Response Rates and Fewer Complications Than Standard Induction in AML

Ianalumab Plus Eltrombopag Extends Time to Treatment Failure in ITP